CDTX Insider Trading

Insider Ownership Percentage: 7.64%
Insider Buying (Last 12 Months): $105,680.00
Insider Selling (Last 12 Months): $86,231.88

Cidara Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Cidara Therapeutics Share Price & Price History

Current Price: $20.89
Price Change: Price Decrease of -0.23 (-1.09%)
As of 04/30/2025 05:00 PM ET

This chart shows the closing price history over time for CDTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$20.89Closing price on 04/30/25:

SEC Filings (Institutional Ownership Changes) for Cidara Therapeutics (NASDAQ:CDTX)

35.82% of Cidara Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CDTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$79Mbought$1.42MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More on Cidara Therapeutics

Today's Range

Now: $20.89
Low: $20.00
High: $21.05

50 Day Range

MA: $20.92
Low: $16.43
High: $24.90

52 Week Range

Now: $20.89
Low: $10.14
High: $28.42

Volume

59,424 shs

Average Volume

71,440 shs

Market Capitalization

$228.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Who are the company insiders with the largest holdings of Cidara Therapeutics?

Cidara Therapeutics' top insider investors include:
  1. Jeffrey Stein (CEO)
  2. Taylor Sandison (Insider)
  3. Leslie Tari (Insider)
  4. Shane Ward (COO)
  5. Preetam Shah (CFO)
Learn More about top insider investors at Cidara Therapeutics.